Dr. Natasha Ryz, a Vitality research advisor, will present a case study report on cannabinoid treatment for pediatric Crohn’s disease
LOS ANGELES, CA – (June 21, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, announced today that Company Advisor Dr. Natasha Ryz will be presenting at an international research symposium in Montreal, Canada.
Dr. Ryz will provide a poster presentation titled “Cannabinoid Treatment Induces Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease: A Case Report.” The case report provides clinical results describing a 13-year old boy with drug-resistant Crohn’s disease that achieved disease remission after cannabinoid treatment. Dr. Ryz holds a Ph.D. in Experimental Medicine from the University of British Columbia, where she was a Vanier Scholar.
The scientific meeting is the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS), and will be held at Le Centre Sheraton Montréal June 23-26, 2017 (www.icrs2017.org). The ICRS is an international association of active researchers that study cannabinoids, and the research program at this year’s conference includes several presentations related to gastroenterology and inflammatory bowel disease. This includes presentations by independent investigators that will describe basic research on the dynamic regulation of the endocannabinoid system in colitis, and clinical research on the effects of cannabis on drug-resistant ulcerative colitis.
About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.